All In Biotech

Drug Trial Radar · NCT04399837

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Jun 4, 2020

Primary completion

Nov 23, 2022

Study completion Nov 23, 2022

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost clear when they join the study. The purpose of the study is to test 3 different doses of a medicine called spesolimab and to see whether it helps to prevent GPP flare-ups. Participants are put into 4 groups by chance. Three groups get different doses of spesolimab. The fourth group gets a placebo. Placebo looks like spesolimab but does not contain any medicine. Spesolimab and placebo are given as an injection under the skin. Participants are in the study for about 1 year and 4 months. During this time, they visit the study site about 15 times. For the first 11 months, participants get spesolimab or placebo injections every month. At the study visits, the doctors check participants' skin for signs of a new GPP flare-up. The doctors also check the general health of the participants. If a participant has a GPP flare-up during the study, more visits may be necessary. In case of a flare-up, participants get a dose of spesolimab as an infusion into a vein.

Conditions

  • Generalized Pustular Psoriasis

Interventions

  • SpesolimabDrug

    Solution for injection

  • PlaceboDrug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Generalized Pustular Psoriasis (GPP) FlareTime frame: GPPGA was regularly assessed at baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Patients could come to site for flare confirmation anytime as unscheduled visit. Visit window was ±7 days.

Locations

72 sites in 23 countries. Site status is shown where the registry gives one.

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Buenos Aires Skin S.A.

    CABA, Argentina

  • Hospital Italiano de Buenos Aires

    CABA, Argentina

  • Brussels - UNIV Saint-Luc

    Brussels, Belgium

  • Clínica Dermacross S.A.

    Vitacura, Chile

  • Sun yet-sen Memorial Hospital, Sun yet-sen Univesity

    Guangzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • The First Hospital of China Medical University

    Shenyang, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, China

  • Second Affiliated Hospital of Xi'an JiaoTong University

    Xi'an, China

  • HOP l'Archet

    Nice, France

  • HOP Saint-Louis

    Paris, France

  • Fachklinik Bad Bentheim

    Bad Bentheim, Germany

  • Universitätsklinikum Bonn AöR

    Bonn, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Klinikum der Universität München - Campus Innenstadt

    München, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Klinikum Oldenburg AöR

    Oldenburg, Germany

  • Universitätsklinikum Würzburg AÖR

    Würzburg, Germany

  • General Hospital of Thessaloniki "Ippokrateio"

    Thessaloniki, Greece

  • Istituto Clinico Humanitas

    Rozzano (MI), Italy

  • Nagoya City University Hospital

    Aichi, Nagoya, Japan

  • Kyushu Rosai Hospital

    Fukuoka, Kitakyushu, Japan

  • Tokyo Medical University Ibaraki Medical Center

    Ibaraki, Inashiki-gun, Japan

  • Saitama Medical University Hospital

    Saitama, Iruma-gun, Japan

  • Tokyo Medical University Hachioji Medical Center

    Tokyo, Hachioji, Japan

  • Tokyo Medical University Hospital

    Tokyo, Shinjuku-ku, Japan

  • Hospital Raja Permaisuri Bainun

    Ipoh, Malaysia

  • Hospital Sultanah Aminah

    Johor Bahru, Malaysia

  • Hospital Sultan Ismail

    Johor Bahru, Malaysia

  • Queen Elizabeth Hospital

    Kota Kinabalu, Malaysia

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • Hospital Pakar Sultanah Fatimah

    Muar town, Malaysia

  • Hospital Pulau Pinang

    Pulau Pinang, Malaysia

  • Centro de Investigación de Enfermedades Autoinmunes S.C.

    Guadalajara, Mexico

  • Hospital Universitario Dr Jose Eleuterio Gonzalez

    Monterrey, Mexico

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.